Hitachi Hard Drive Diagnostics Tool 2020

Lab Reagents

Hitachi Exocomplete Laboratories manufactures the hitachi hard drive diagnostics tool 2020 reagents distributed by Genprice. The Hitachi Hard Drive Diagnostics Tool 2020 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Hitachi Exocomplete. Other Hitachi products are available in stock. Specificity: Hitachi Category: Hard Group: Drive Diagnostics

Drive Diagnostics information

GRIN2A Blocking Peptide

33R-2020 100 ug
EUR 180
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of GRIN2A antibody, catalog no. 70R-5207

SNCG antibody

10R-2020 100 ul
EUR 349
Description: Mouse monoclonal SNCG antibody

TADA3 antibody (FITC)

60R-2020 100 ug
EUR 327
Description: Rabbit polyclonal TADA3 antibody (FITC)

EED Polyclonal Antibody

A-2020 100 µl
EUR 616.95
Description: kits suitable for this type of research

EpiQuik Tissue Methylated DNA Immunoprecipitation Kit

P-2020 48 Reactions
EUR 889.55
Description: The best epigenetics products

3D Cell Culture Gel 2ml x(soft+medium+hard)

P720SMH-6 - Ask for price

Human merozoite surface protein-1 ,MSP-1 ELISA kit

201-12-2020 96 tests
EUR 440
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

p-Nitrophenyl phosphate (pNPP) substrate 20 mg

09-2020-100 20 mg
EUR 260

p-Nitrophenyl phosphate (pNPP) substrate 20 mg

09-2020-24 20 mg
EUR 100

Anti-GD3 (Ecromeximab)-MC-MMAF ADC

ADC-W-2020 1mg Ask for price
Description: This ADC product is comprised of an anti-GD3 monoclonal antibody conjugated via a MC linker to MMAF


EUR 60
Description: Sealing Products; Sealing films - Axygen

SARS-CoV-2 Rapid Antigen Test Nasal

9901-NCOV-03G 25 Tests/Kit
EUR 94
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

Mouse Anti-Human CD57 monoclonal antibody, clone JID650

CABT-L2966-100uL500uL 100 uL, 500 uL
EUR 502

Mouse Anti-Human Uroplakin III monoclonal antibody, clone JID792

CABT-L2967-100uL500uL 100 uL, 500 uL
EUR 502

Mouse Anti-Human HPV16 monoclonal antibody, clone JID714

CABT-L2968-100uL500uL 100 uL, 500 uL
EUR 502

Mouse Anti-Human CD3 monoclonal antibody, clone JID645

CABT-L2969-100uL500uL 100 uL, 500 uL
EUR 502

Mouse Anti-Human HAS monoclonal antibody, clone JID702

CABT-L2970-100uL500uL 100 uL, 500 uL
EUR 502